| 0.611 -0.037 (-5.71%) | 12-07 15:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.81 | 1-year : | 0.95 |
| Resists | First : | 0.69 | Second : | 0.81 |
| Pivot price | 0.6  |
|||
| Supports | First : | 0.57 | Second : | 0.5 |
| MAs | MA(5) : | 0.63 |
MA(20) : | 0.58 |
| MA(100) : | 0.83 |
MA(250) : | 1.56 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 62.1 |
D(3) : | 67.6 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 8.53 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PALI ] has closed below upper band by 35.8%. Bollinger Bands are 78.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.64 - 0.65 | 0.65 - 0.65 |
| Low: | 0.6 - 0.61 | 0.61 - 0.61 |
| Close: | 0.62 - 0.62 | 0.62 - 0.63 |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Fri, 10 Nov 2023
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook - GlobeNewswire
Wed, 11 Oct 2023
Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference - Yahoo Finance
Thu, 14 Sep 2023
Insider Buying: John Finley Acquires 15,000 Shares of Palisade Bio Inc - Yahoo Finance
Mon, 11 Sep 2023
What's Happening With Palisade Bio Stock? - Palisade Bio (NASDAQ:PALI) - Benzinga
Thu, 07 Sep 2023
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules - GlobeNewswire
Thu, 07 Sep 2023
Why Is Palisade Bio (PALI) Stock Down 46% Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 9.08e+006 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 215 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.34e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 360.7 % |
| Return on Equity (ttm) | -50.3 % |
| Qtrly Rev. Growth | 250000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -70.32 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.56 |
| Dividend | 0 |
| Forward Dividend | 66630 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|